Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study
Abstract It remains unknown whether the early response to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) management in malignancies links to long‐term survival. The objective of this study was to investigate the survival rates and predictive factors of early respon...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5268 |
| _version_ | 1797893204562935808 |
|---|---|
| author | Ryuta Sobu Kazuyuki Numakura Sei Naito Shingo Hatakeyama Renpei Kato Tomoyuki Koguchi Takahiro Kojima Yoshihide Kawasaki Syuya Kandori Sadafumi Kawamura Yoichi Arai Akihiro Ito Hiroyuki Nishiyama Yoshiyuki Kojima Wataru Obara Chikara Ohyama Norihiko Tsuchiya Tomonori Habuchi |
| author_facet | Ryuta Sobu Kazuyuki Numakura Sei Naito Shingo Hatakeyama Renpei Kato Tomoyuki Koguchi Takahiro Kojima Yoshihide Kawasaki Syuya Kandori Sadafumi Kawamura Yoichi Arai Akihiro Ito Hiroyuki Nishiyama Yoshiyuki Kojima Wataru Obara Chikara Ohyama Norihiko Tsuchiya Tomonori Habuchi |
| author_sort | Ryuta Sobu |
| collection | DOAJ |
| description | Abstract It remains unknown whether the early response to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) management in malignancies links to long‐term survival. The objective of this study was to investigate the survival rates and predictive factors of early response in patients with metastatic renal cell carcinoma (mRCC) managed by VEGFR‐TKIs. From Jan. 2008 to Oct. 2018, 496 patients were treated with VEGFR‐TKIs as first‐line treatment at the eight Japanese hospitals (Michinoku RCC). Early cessation was defined as VEGFR‐TKIs being given up within 3 months after their initiation. The number of patients in early cessation VEGFR‐TKIs (Cohort I) was 173 (34.9%), and in long‐term use (Cohort II) was 323 (65.1%). The cancer‐specific survival (CSS) and overall survival (OS) were better in Cohort II. IMDC Poor‐risk was at risk of early cessation of a first‐line VEGFR‐TKI. Axitinib was the most preferred drug for long‐term treatment. On closer examination, both Cohort I and II were divided into two groups, the patients ceased VEGFR‐TKI due to adverse events (Group A [67 from Cohort I] and Group C [51 from Cohort II]) and disease progression (Group B [106 from Cohort I] and Group D [272 from Cohort II]). Despite that the cessation was adverse events, CSS and OS in Group A were worse than both Group C and D. Axitinib was administered with the safer profile. IMDC Poor risk was the risk factor for the early disease progression. Managing early adverse events may contribute to a better prognosis in mRCC patients treated VEGFR‐TKIs. |
| first_indexed | 2024-04-10T06:49:10Z |
| format | Article |
| id | doaj.art-24099fdcb8384362b97b3056f59518f8 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T06:49:10Z |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-24099fdcb8384362b97b3056f59518f82023-02-28T08:51:57ZengWileyCancer Medicine2045-76342023-02-011244100410910.1002/cam4.5268Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective studyRyuta Sobu0Kazuyuki Numakura1Sei Naito2Shingo Hatakeyama3Renpei Kato4Tomoyuki Koguchi5Takahiro Kojima6Yoshihide Kawasaki7Syuya Kandori8Sadafumi Kawamura9Yoichi Arai10Akihiro Ito11Hiroyuki Nishiyama12Yoshiyuki Kojima13Wataru Obara14Chikara Ohyama15Norihiko Tsuchiya16Tomonori Habuchi17Department of Urology Akita University Graduate School of Medicine Akita JapanDepartment of Urology Akita University Graduate School of Medicine Akita JapanDepartment of Urology Yamagata University Faculty of Medicine Yamagata JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Iwate Medical University Morioka JapanDepartment of Urology Fukushima Prefectural Medical University Fukushima JapanDepartment of Urology Aichi Cancer Center Nagoya JapanDepartment of Urology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Urology and Andrology Tsukuba University Graduate School of Comprehensive Human Sciences Tsukuba JapanDepartment of Urology Miyagi Cancer Center Natori JapanDepartment of Urology Miyagi Cancer Center Natori JapanDepartment of Urology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Urology and Andrology Tsukuba University Graduate School of Comprehensive Human Sciences Tsukuba JapanDepartment of Urology Fukushima Prefectural Medical University Fukushima JapanDepartment of Urology Iwate Medical University Morioka JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Yamagata University Faculty of Medicine Yamagata JapanDepartment of Urology Akita University Graduate School of Medicine Akita JapanAbstract It remains unknown whether the early response to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) management in malignancies links to long‐term survival. The objective of this study was to investigate the survival rates and predictive factors of early response in patients with metastatic renal cell carcinoma (mRCC) managed by VEGFR‐TKIs. From Jan. 2008 to Oct. 2018, 496 patients were treated with VEGFR‐TKIs as first‐line treatment at the eight Japanese hospitals (Michinoku RCC). Early cessation was defined as VEGFR‐TKIs being given up within 3 months after their initiation. The number of patients in early cessation VEGFR‐TKIs (Cohort I) was 173 (34.9%), and in long‐term use (Cohort II) was 323 (65.1%). The cancer‐specific survival (CSS) and overall survival (OS) were better in Cohort II. IMDC Poor‐risk was at risk of early cessation of a first‐line VEGFR‐TKI. Axitinib was the most preferred drug for long‐term treatment. On closer examination, both Cohort I and II were divided into two groups, the patients ceased VEGFR‐TKI due to adverse events (Group A [67 from Cohort I] and Group C [51 from Cohort II]) and disease progression (Group B [106 from Cohort I] and Group D [272 from Cohort II]). Despite that the cessation was adverse events, CSS and OS in Group A were worse than both Group C and D. Axitinib was administered with the safer profile. IMDC Poor risk was the risk factor for the early disease progression. Managing early adverse events may contribute to a better prognosis in mRCC patients treated VEGFR‐TKIs.https://doi.org/10.1002/cam4.5268axitinibearly responsemetastatic renal cell carcinomaVEGFR‐TKI |
| spellingShingle | Ryuta Sobu Kazuyuki Numakura Sei Naito Shingo Hatakeyama Renpei Kato Tomoyuki Koguchi Takahiro Kojima Yoshihide Kawasaki Syuya Kandori Sadafumi Kawamura Yoichi Arai Akihiro Ito Hiroyuki Nishiyama Yoshiyuki Kojima Wataru Obara Chikara Ohyama Norihiko Tsuchiya Tomonori Habuchi Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study Cancer Medicine axitinib early response metastatic renal cell carcinoma VEGFR‐TKI |
| title | Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study |
| title_full | Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study |
| title_fullStr | Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study |
| title_full_unstemmed | Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study |
| title_short | Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study |
| title_sort | clinical impact of early response to first line vegfr tki in patients with metastatic renal cell carcinoma on survival a multi institutional retrospective study |
| topic | axitinib early response metastatic renal cell carcinoma VEGFR‐TKI |
| url | https://doi.org/10.1002/cam4.5268 |
| work_keys_str_mv | AT ryutasobu clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT kazuyukinumakura clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT seinaito clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT shingohatakeyama clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT renpeikato clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT tomoyukikoguchi clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT takahirokojima clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT yoshihidekawasaki clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT syuyakandori clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT sadafumikawamura clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT yoichiarai clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT akihiroito clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT hiroyukinishiyama clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT yoshiyukikojima clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT wataruobara clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT chikaraohyama clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT norihikotsuchiya clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy AT tomonorihabuchi clinicalimpactofearlyresponsetofirstlinevegfrtkiinpatientswithmetastaticrenalcellcarcinomaonsurvivalamultiinstitutionalretrospectivestudy |